Key Takeaways BEAM reported BEACON updates with HbF gains, lower HbS and sustained anemia resolution in SCD.Beam Therapeutics secured orphan drug and RMAT designations for risto-cel from the FDA.BEAM is advancing early-stage programs for GSD1a and AATD, with pipeline execution key heading into 2026.Beam Therapeutics (BEAM) is engaged in developing investigational gene therapy candidates that are currently in early-to-mid-stage development for treating certain hematology and genetic diseases.The company’s pr ...